News

A case study illustrated the difficulty of diagnosing systemic mastocytosis (SM), particularly in children.

Patients with advanced mastocytosis showed significantly higher sclerostin concentrations, especially in those with bone disease.

Patients with indolent systemic mastocytosis appear to have a quality of life comparable to that of patients with lymphoma and leukemia

Improved diagnostics resulted in a higher prevalence of mastocytosis, including SM, than earlier reported, a new study said.

A new study is recruiting participants and will evaluate the safety of avapritinib in treating SM over a period of four years.

A clinical trial demonstrated that bezuclastinib significantly improved symptoms and biomarkers of systemic mastocytosis.

Ultrasensitive duplex sequencing could improve diagnosis of indolent systemic mastocytosis in patients with low variant allele frequencies.

Patients with systemic mastocytosis (SM) showed promising overall response rates to treatment with bezuclastinib, its maker announced.

Some medical specialists lack awareness of systemic mastocytosis (SM) because of its association with various symptoms.

Avapritinib significantly improved overall survival in patients with SM compared to midostaurin or best available therapy.